LAMININ RECEPTOR IN BREAST TISSUE, BENIGN AND MALIGNANT TUMORS

层粘连蛋白是基底膜的主要糖蛋白， 饱和结合到某些肿瘤和正常的表面， 细胞 各种细胞类型（即人胰腺细胞）的检查 癌、黑色素瘤和膀胱癌）通过活细胞结合 技术表明受体的数量为50- 110，000个/ 根据细胞类型。 在我们的实验室里，层粘连蛋白重新- 已从人乳腺癌细胞中分离出受体， 组织和小鼠黑素瘤细胞。 受体和随后的 配体结合已经被暗示在 肿瘤细胞附着是肿瘤侵袭的步骤之一， 转移 这项研究旨在测量和校正- 乳腺组织的晚期层粘连蛋白受体结合能力 临床信息。 层粘连蛋白受体结合能力显著 在良性、恶性和正常人类乳腺组织之间存在差异。 初步研究表明特异性层粘连蛋白增加了50倍 恶性乳腺组织与良性乳腺组织中的结合活性。 这些 研究结果表明，在序列中可能存在一个干预位点， 肿瘤的侵袭。

Laminin, a major glycoprotein of basement membranes, exhibits saturable binding to the surface of certain neoplastic and normal cells. Examination of various cell types (i.e. human pancreatic carcinoma, melanoma and bladder carcinoma) via live cell binding techniques indicate the number of receptors to be 50-110,000 per cell depending on cell type. In our laboratory, the laminin re- ceptor has been isolated from human breast carcinoma cells and tissue and mouse melanoma cells. The receptor and subsequent ligand binding have been implicated to play an important role in tumor cell attachment, one of the steps in tumor invasion and metastasis. The proposed study is designed to measure and corre- late laminin receptor binding capacity of breast tissues with clinical information. Laminin receptor binding capacity markedly differs between benign, malignant and normal human breast tissue. Preliminary studies indicate a 50-fold increase in specific laminin binding activity in malignant versus benign breast tissues. These findings suggest a site for possible intervention in the sequence of tumor invasion.